About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 96 record(s)
Req # A-2021-001758
Adverse Drug Reaction (ADR). Report number: E2B_04730060.Organization: Health Canada
April 2022
Req # A-2021-001772
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: 967214, E2B_04283693.Organization: Health Canada
April 2022
Req # A-2021-001779
Adverse Drug Reactions (ADRs) for ANTI-THYMOCYTE GLOBULIN (RABBIT). Report numbers: E2B_04314477, E2B_04315060, E2B_04314360, E2B_04314992, E2B_03542554, 000956693, E2B_04581916, 000964162.Organization: Health Canada
April 2022
Req # A-2021-001784
Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: E2B_04359867, 000966630, E2B_04439754, 000960606, E2B_04408157, 000963248, E2B_04336793, 000959498, 000959460, 000959916, E2B_04442993, E2B_04549499.Organization: Health Canada
April 2022
Req # A-2021-001795
Adverse Drug Reaction (ADR) for HYDROXYCHLOROQUINE SULFATE. Report number: E2B_04413148.Organization: Health Canada
April 2022
Req # A-2021-001798
Adverse Drug Reactions (ADRs) for METRONIDAZOLE. Report numbers: E2B_04455274, E2B_04455728, E2B_04195130, E2B_04195142, E2B_04195226, E2B_04213632, E2B_04229091, E2B_04589470, 000966671.Organization: Health Canada
April 2022
Req # A-2021-001799
Adverse Drug Reactions (ADRs) for METRONIDAZOLE. Report numbers: 000958682, E2B_04335276, E2B_04420970, 000951874, E2B_04488537, E2B_04419410, E2B_04420402, E2B_04385664, E2B_04617068, E2B_04594653, E2B_04556592.Organization: Health Canada
April 2022
Req # A-2021-001801
Adverse Drug Reactions (ADRs) for SARILUMAB, SODIUM FERRIC GLUCONATE COMPLEX, TERIFLUNOMIDE. Report numbers: 000954857, 000952146, 000958838, E2B_04203225.Organization: Health Canada
April 2022
Req # A-2021-001820
Adverse Drug Reaction (ADR) for DESOXIMETASONE. Report number: E2B_00370241.Organization: Health Canada
April 2022
Req # A-2021-001825
Adverse Drug Reactions (ADRs). Report numbers: E2B_03369832, E2B_01531780, E2B_03895315.Organization: Health Canada
April 2022